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Purpose: Patients with uncontrolled asthma despite high doses of inhaled corticosteroid 
therapy plus another controller are defined as severe asthmatics. Tiotropium bromide respi-
mat (TBR) is the only long-acting muscarinic antagonists (LAMA) approved for severe 
asthma. The aim of this study was to explore the frequency of severe asthmatics treated with 
TBR and characterize their clinical features in a real-life, registry-based setting.
Materials and Methods: Baseline data from the Severe Asthma Network in Italy (SANI) 
registry have been analyzed to determine the use of TBR and other LAMA, and to compare 
clinical, functional and inflammatory features associated with the use of LAMA.
Results: Among a total of 698 enrolled patients, 35.9% were treated with LAMA (23.3% 
TBR, 4.5% tiotropium bromide handihaler, 4.5% aclidinium, 3.4% glycopyrronium bromide 
0.3% umeclidinium bromide). Age of asthma onset was higher in patients taking LAMA, 
whom, compared to others were more frequently former smokers. They also had a higher 
annual exacerbation rate, experienced worst asthma control, worst disease-related quality of 
life and poorer lung function. Bronchiectasis was more frequently found in LAMA users 
(25.9% vs 13.1%).
Conclusion: TBR is still underused in severe asthma in a real-life setting, while a relevant 
proportion of patients are treated with other LAMA that are not approved for severe asthma 
treatment. Patients taking LAMA have features characteristic of even more severe asthma.
Keywords: severe asthma, registry, long-acting muscarinic antagonists, real-life
Introduction
Though the prevalence of severe asthma is less than 5% among patients with 
persistent asthma, this condition accounts for an excessive burden on disease- 
related healthcare resources and costs.1–5 In order to correctly define a patient as 
a severe asthmatic, several possible aggravating and/or confounding factors should 
be systematically addressed (including possible misdiagnosis, proper treatment of 
relevant comorbidities, treatment adherence and inhaler technique, relevant envir-
onmental exposures, etc.) as suggested, for example, by the Nordic consensus 
statement on the systematic assessment and management of possible severe asthma 
in adults,6 resulting in a lower prevalence of severe refractory asthma (ie, 3.6% as 
reported by Hekking et al).1 The recent availability of anti-IgE and anti-IL-5 
monoclonal antibodies represents a significant step forward in the treatment of 
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this condition reducing exacerbation rates as well as hos-
pitalizations but their high costs remain their main 
drawback.2–5 The eligible population for biologic agents 
is suggested to be around 30–40% for anti-IgE and 
25–55% for anti-IL5.7–9
According to the Global Initiative for Asthma (GINA) 
recommendations,10 severe asthmatic patients can be 
labelled as step 4 or step 5 depending on their level of 
asthma control under medium-to-high dose-inhaled corti-
costeroids (ICS)/long-acting beta2-agonists (LABA). For 
both step 4 and step 5 Tiotropium bromide Respimat ® 
(TBR), a long-acting muscarinic antagonist (LAMA) is an 
add-on therapeutic option. LAMA have long since been 
approved as a maintenance therapy in chronic obstructive 
pulmonary disease (COPD),11,12 considering their action 
on airflow limitation and exercise tolerance 
improvement.13,14
New generations of selective LAMA molecules act 
on three out of the five identified muscarinic receptors 
directly involved in mucus secretion and airway smooth 
muscle contraction. The binding of acetylcholine (ACh) 
to the M3 and, in a lesser extent, to the M1 muscarinic 
receptors, results in smooth muscle contraction and 
mucus secretion. On the other hand, activation of M2 
receptors reduces the release of ACh. Tiotropium has 
a high selectivity for M3 and M1 receptors, while it 
rapidly dissociates from M2 receptors,15 making it an 
optimal anticholinergic drug. Since the approval of tio-
tropium in COPD, many studies have analyzed its effi-
cacy in asthma, and a single daily dose of Tiotropium 
was found to be effective in the treatment of nocturnal 
asthma16–18 as well as in the improvement of lung func-
tion tests,19 both in the adult and adolescent 
population.20
In the 2017 update of GINA recommendations, TBR 
has been suggested as an add-on treatment for severe 
asthma.10 Many studies analyzed the comparison between 
LABA and LAMA as add-on therapy to ICS in asthmatic 
patients,21 and the efficacy of LAMA in a real-life setting, 
showing a significant improvement in mean FEV1 values, 
a reduction in asthma exacerbations, as well as 
a subjective improvement in exercise tolerance and 
cough.21–23,23,24
The present study was carried out in a large population 
of the Severe Asthma Network in Italy (SANI)25 to deter-
mine the frequency of TBR treatment in severe asthmatics 




SANI is a web-based observatory that collects demo-
graphic, clinical and functional data, as well as inflamma-
tory biomarkers of patients with severe asthma, defined 
according to European Respiratory Society (ERS)/ 
American Thoracic Society (ATS) classification (asthma 
which requires treatment with high dose ICS plus 
a second controller, and/or systemic corticosteroids, to pre-
vent it from becoming “uncontrolled” or which remains 
“uncontrolled” despite this therapy)26 and aged >12 years, 
recruited by accredited centers homogeneously spread out 
on the national territory.25 Considering the real-life nature 
of the SANI registry, no exclusion criteria (including the 
possibility to have received a diagnosis of asthma-COPD 
overlap) were present in the protocol.25 In the SANI registry 
demographic, clinical (ie, allergic sensitizations, comorbid-
ities, information on asthma exacerbations, asthma control, 
asthma-related quality of life . . .), functional (lung function 
parameters), inflammatory (ie, blood eosinophils, serum 
IgE, exhaled nitric oxide) and asthma-related treatment 
data are collected.25
Baseline data from the SANI registry have been ana-
lyzed to assess the frequency of LAMA treatment as well 
as the clinical features associated with their use in severe 
asthmatics.
Patients’ recruitment started in late 2016 – beginning 
of 2017, just after the first Center received the Ethics 
Committee approval. Data extraction for this analysis 
was performed in March 2019.
Ethical Issues
The SANI registry was constructed according to the 
declarations of Helsinki and Oviedo, and was set up 
according to the 3rd Edition Recommendation on regis-
tries for evaluating patient outcomes published by the 
Effective Health Care Program of the Agency for 
Healthcare Research and Quality.27 The protocol has 
been performed according to the principles and procedures 
of the Good Clinical Practice28 and in accordance with the 
Italian laws (Legislative Decree n.211, June 24, 2003; 
Legislative Decree.n.200 November 6, 2007; Ministry 
Decree December 21, 2007). The protocol has been 
approved by the Central Ethics Committee (“Area Vasta 
Nord-Ovest Toscana” Ethics Committee; protocol number: 
study number 1245/2016, protocol number: 73714) and the 
enrollment in the other Center started upon approval of 
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local Ethics Committees. All enrolled patients signed an 
informed consent.
Statistical Analysis
Statistical analysis was performed using SPSS 21.0 soft-
ware (SPSS, Chicago, IL, USA). The Kolmogorov– 
Smirnov test was used to evaluate the normality of dis-
tribution of each continuous variable, and depending on 
the result of this test, the Student’s t-test or Mann–Whitney 
test was used to compare variables. Categorical variables 
were compared with the Fisher exact test. A p-value < 0.05 
was considered statistically significant.
Results
Among a total of 698 enrolled patients by March 2019, 
35.9% were treated with LAMA (23.3% TBR, 4.5% 
Tiotropium bromide Handihaler, 4.5% Aclidinium, 3.4% 
Glycopyrronium bromide 0.3% Umeclidinium bromide) 
(Figure 1). As shown in Table 1 patients taking LAMA 
showed a significantly higher age of asthma onset, and 
were more frequently former smokers. They reported 
a higher annual exacerbation rate, showed worst asthma 
control (assessed with both Asthma Control Test, ACT,29 
and Asthma Control Questionnaire, ACQ)30 as well as worst 
disease-related quality of life (assessed by Asthma Quality 
of Life Questionnaire, AQLQ)31 (Table 2). LAMA users had 
a significantly lower basal FEV1% of predicted value (Table 
3), had more frequently concomitant bronchiectasis, and 
were more frequently treated with oral corticosteroids and 
biological agents (Table 2). No significant difference has 
been recorded in regard to biomarkers of type-2 inflamma-
tion, such as serum total IgE, blood eosinophil count and 
exhaled nitric oxide (FENO) (Table 2).
No significant difference was found, for any parameter, 
between patients using TBR and those treated with other 
LAMA molecules and devices.
Discussion
Our study highlights that within the population of SANI 
registry, around one out of three patients were undergoing 
LAMA therapy; this is in line with what was reported by 
other national registries for severe asthma, with LAMA 
treatment being used in 13–45% of patients depending on 
the country.32 That group was overall characterized by 
more severe disease in terms of lung function, exacerba-
tions, patients’ reported outcomes and required therapy; in 
fact, the prescription rate of biological agents, in particular 
anti-IL5 agents, and the use of systemic corticosteroids 
were higher in patients under LAMA therapy. Worthy of 
mention, the distribution of inflammatory biomarkers in 
that sub-population was very similar to the overall severe 
asthmatics population sample.
TBR has been proven to be an effective add-on therapy 
in adult patients with asthma treated with ICS/LABA 
combination reducing the exacerbation rate as well as 
ameliorating lung function.21,22 Its clinical efficacy was 
confirmed in adolescents even if at a lesser extent.20 
Similar positive results were also reported in a real-life 
setting where the significant reduction of exacerbations 
was confirmed by a reduction of antibiotic course and 
oral steroid usage.24
That body of evidence provided the rationale for 
including TBR as an add-on recommended treatment for 
GINA step 4 and 5 patients,10 when medium-to-high dose 
ICS-LABA treatment is not associated with an optimal 
disease control. Interestingly, GINA recommendations 
Figure 1 Prevalence of patients with severe asthma treated with long-acting anti-muscarinic agents (LAMA).
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place TBR before the biologic treatment option. The ERS/ 
ATS guidelines on the management of severe asthma also 
suggest the use of TBR in patients with severe uncon-
trolled asthma.26
Despite these findings and the evidence of its mechan-
isms of action, which may account for its efficacy in 
asthma, our study reports that TBR is still underused, 
while a relevant proportion of patients are treated with 
other LAMA that are not currently approved for severe 
asthma. Similarly, a recent investigation conducted in the 
United States highlighted that a triple combination includ-
ing ICS, LABA and LAMA had been prescribed to no 
more than 27% of patients undergoing biologic 
treatment.33 The reason for the low prescription rate of 
TBR is not easy to understand. When looking at the study 
population, both in our dataset and in real-life literature,33 
it is quite apparent that severe asthmatics treated with 
LAMA are affected by a more difficult-to-control disease, 
in terms of exacerbations, lung function and quality of life.
Furthermore, in our cohort of severe asthmatics, those 
treated with LAMA were not characterized by more severe 
Type-2 inflammation, at least according to the evaluated 
biomarkers (total IgE, blood eosinophils count, FENO), 
even if the entire study population showed high frequency 
of Type-2 late-onset severe asthma. Considering these 
results together, the prescription of LAMA does not 
seem oriented by specific Type-2 biomarkers. The high 
proportion of Type-2 late-onset severe asthmatics in our 
registry population might be interpreted as a potential trait 
accounting for less efficacy of LAMA; however, patients 
requiring LAMA for achieving a better asthma control 
seem to express a different “sub-phenotype”, characterized 
by lower Type-2 inflammatory traits, such as former smok-
ing habit like in our data, prompting the clinical suspect of 
a possible Asthma-COPD overlap at least in a proportion 
of these patients. In this regard, the long-standing use of 
LAMA in COPD and some similarities between 
Table 2 Clinical and Inflammatory Characteristics of Patients 




LAMA Users p values
Annual exacerbation rate 2.4 ± 3.2 3.9 ± 7.6 <0.01
ACT 18.4 ± 5.2 17.2 ± 5.2 0.01
ACQ 2.5 ± 1.5 2.9 ± 1.5 0.01
AQLQ 4.7 ± 1.4 4.2 ± 1.3 <0.01
Exhaled nitric oxide (FENO), ppb 47.8 ± 50.1 40.7 ± 35.4 0.20
Concomitant bronchiectasis (%) 13.1 25.5 <0.01
Concomitant GERD (%) 54.0 58.4 0.15
Concomitant Rhinitis (%) 61.1 55.9 0.14
Concomitant CRSwNP (%) 38.4 45.9 0.08
Concomitant Atopic Dermatitis (%) 4.8 5.6 0.39
Blood eosinophils (cells/mcl) 453.9 ± 559.7 562.9 ± 668.3 0.03
Serum total IgE (UI/mL) 494.1 ± 876.8 417.2 ± 823.6 0.35
Inhaled corticosteroids (ICS) 
mean dose (mcg, Fluticasone 
equivalents)
1111.4 ± 644.8 1079.7 ± 541.4 0.54
Long term oral corticosteroids 
(OCS) use (%)
36.9 62.9 <0.01
OCS mean dose (mg, Prednisone 
equivalents)
16.3 ± 18.7 13.4 ± 9.3 0.18













Notes: Statistically significant p values are reported in bold font. Data about ACT 
were available in 351 patients, ACQ in 390, AQLQ in 423, FENO in 269, blood 
eosinophils in 459, serum total IgE in 438.
Table 1 Demographic Characteristics of Patients with Severe 









Mean age (years) 56.1 ± 14.0 54.1 ± 12.1 0.08
Females (%) 59.3 62.3 0.37
Atopy (%) 72.8 78.8 0.36
BMI 24.4 ± 4.5 27.9 ± 24.4 0.06
Onset of asthma (years) 32.4 ± 16.6 35.3 ± 16.6 <0.01
Patients with late-onset 
asthma (age of onset ≥ 40 
years) (%)
44.1 38.3 0.188








Note: Statistically significant p values are reported in bold font.
Table 3 Functional Characteristics of Patients with Severe 







FEV1 (liters) 2.2 ± 0.8 1.9 ± 0.7 <0.01
FEV1% predicted 75.5 ± 19.8 70.3 ± 20.6 <0.01
FEV1/FVC, % 67.0 ± 12.0 65.1 ± 14.0 0.12
Notes: Statistically significant p values are reported in bold font. Data about 
spirometric 474 patients. 
Abbreviations: ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; 
AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; CRSwNP, 
chronic rhinosinusitis with nasal polyps; FENO, exhaled nitric oxide; GERD, gastro- 
esophageal reflux disease; ICS, inhaled cortico steroids; OCS, oral cortico steroids.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                     
Journal of Asthma and Allergy 2020:13 602
Puggioni et al                                                                                                                                                         Dovepress
neutrophilic phenotype of severe asthma and COPD may 
account for this finding. Unfortunately, information on the 
concomitant presence of asthma and COPD (Asthma- 
COPD overlap) is missing in our registry.
The efficacy of TBR has been proved independently of 
age, atopic status34 or body mass index,35 and therefore its 
use should be implemented as an add-on treatment strategy 
in order to improve lung function and exacerbation rate in 
different patient groups, independently of the indication 
for biological agents’ treatment.
It is worthy of mention that the current guidelines on 
severe asthma management recommend the use of TBR 
rather than any LAMA.10,26 This recommendation is par-
tially disregarded in our dataset. Especially when talking 
about severe obstructive syndromes, the relevance of the 
device is not negligible. In fact, different devices require 
peculiar conditions in terms of patients’ inhalation flow 
and manual skills in order to obtain an optimal drug 
delivery. According to the available evidence,36 TBR is 
suitable for different patient groups regardless of the inha-
lation flow (>30 or <30 L/min) and specific manual skills 
without impacting the drug delivery efficiency.
Conclusion
In conclusion, our data highlights a low prescription rate 
of TBR for severe asthma patients, despite the evidence 
that this treatment option can have a significant impact on 
severe asthma control.
Limits of our study include the intrinsic nature of real- 
life registry-based studies because of their heterogeneity in 
terms of treated patients and clinical settings, but the 
strength of data derived from disease registries is in their 
ability to provide a precise picture of real clinical 
practice,37 therefore suggesting possible interventions (ie, 
educational interventions for clinicians) in order to 
improve the adherence to guidelines and international 
recommendations.
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